JP2024020372A5 - - Google Patents

Download PDF

Info

Publication number
JP2024020372A5
JP2024020372A5 JP2023193220A JP2023193220A JP2024020372A5 JP 2024020372 A5 JP2024020372 A5 JP 2024020372A5 JP 2023193220 A JP2023193220 A JP 2023193220A JP 2023193220 A JP2023193220 A JP 2023193220A JP 2024020372 A5 JP2024020372 A5 JP 2024020372A5
Authority
JP
Japan
Prior art keywords
concentration
present
pharmaceutical
antibody
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023193220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024020372A (ja
Filing date
Publication date
Priority claimed from JP2021552832A external-priority patent/JP7420827B2/ja
Application filed filed Critical
Publication of JP2024020372A publication Critical patent/JP2024020372A/ja
Publication of JP2024020372A5 publication Critical patent/JP2024020372A5/ja
Pending legal-status Critical Current

Links

JP2023193220A 2019-03-08 2023-11-13 抗il-36r抗体製剤 Pending JP2024020372A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962815405P 2019-03-08 2019-03-08
US62/815,405 2019-03-08
JP2021552832A JP7420827B2 (ja) 2019-03-08 2020-03-05 抗il-36r抗体製剤
PCT/US2020/021059 WO2020185479A1 (en) 2019-03-08 2020-03-05 Anti-il-36r antibody formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021552832A Division JP7420827B2 (ja) 2019-03-08 2020-03-05 抗il-36r抗体製剤

Publications (2)

Publication Number Publication Date
JP2024020372A JP2024020372A (ja) 2024-02-14
JP2024020372A5 true JP2024020372A5 (cg-RX-API-DMAC7.html) 2024-04-02

Family

ID=70009446

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552832A Active JP7420827B2 (ja) 2019-03-08 2020-03-05 抗il-36r抗体製剤
JP2023193220A Pending JP2024020372A (ja) 2019-03-08 2023-11-13 抗il-36r抗体製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021552832A Active JP7420827B2 (ja) 2019-03-08 2020-03-05 抗il-36r抗体製剤

Country Status (14)

Country Link
US (2) US11730812B2 (cg-RX-API-DMAC7.html)
EP (1) EP3934617A1 (cg-RX-API-DMAC7.html)
JP (2) JP7420827B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210137520A (cg-RX-API-DMAC7.html)
CN (1) CN113543772A (cg-RX-API-DMAC7.html)
AU (1) AU2020238676B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016198A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132917A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002331A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192405A1 (cg-RX-API-DMAC7.html)
IL (1) IL286100B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021010783A (cg-RX-API-DMAC7.html)
PH (1) PH12021552150A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020185479A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526410B2 (en) 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
WO2019177883A2 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
US11730812B2 (en) 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations
MX2023000763A (es) 2020-07-17 2023-02-13 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
CN114907477A (zh) * 2021-02-08 2022-08-16 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
BR112023014103A2 (pt) 2021-03-04 2023-10-10 Boehringer Ingelheim Int Métodos para o tratamento de gpp
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
WO2026041035A1 (zh) * 2024-08-20 2026-02-26 江苏恒瑞医药股份有限公司 一种包含il-36r/il-23结合蛋白的药物组合物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE230277T1 (de) * 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
EP1798286B1 (en) 1997-08-01 2011-09-07 Schering Corporation Mammalian cell membrane proteins and related reagents
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
CA2499891A1 (en) 2002-10-03 2004-04-15 Large Scale Biology Corporation Multimeric protein engineering
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8034771B2 (en) 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
JP2010526066A (ja) 2007-04-23 2010-07-29 シェーリング コーポレイション 抗mdl−1抗体
ES2540854T3 (es) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Usos de antagonistas MDL-1
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 il-22, il-17 및 il-1 패밀리 시토킨의 용도
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
EP2473528B1 (en) * 2009-09-03 2014-12-03 Ablynx N.V. Stable formulations of polypeptides and uses thereof
SG184355A1 (en) 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
SI2780373T1 (sl) 2011-11-16 2019-12-31 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
KR102063028B1 (ko) * 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ang2 항체를 함유하는 안정화된 제형
RU2667643C2 (ru) 2012-08-24 2018-09-21 Новартис Аг Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
US20180008707A1 (en) 2015-02-13 2018-01-11 Sanofi Stable liquid formulation for monoclonal antibodies
US10526410B2 (en) 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
US10166993B2 (en) 2015-08-05 2019-01-01 Ford Global Technologies, Llc Customer driving mode for vehicles
EP3601350A1 (en) 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Anti il-36r antibodies combination therapy
WO2019177883A2 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
AU2019236105B2 (en) * 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
KR20210119407A (ko) 2018-12-27 2021-10-05 베링거 인겔하임 인터내셔날 게엠베하 수장 족저 농포증 치료용 항-il-36r 항체
US11730812B2 (en) 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations

Similar Documents

Publication Publication Date Title
CN102946861B (zh) 浓缩蛋白制剂及其用途
KR102436694B1 (ko) 약학 조성물
KR100911091B1 (ko) 항체의 안정화 방법 및 안정화된 용액상 항체 제제
KR101593285B1 (ko) 단일 도메인 항원 결합 분자의 제형
US20200369760A1 (en) Stabilized formulations containing anti-angptl3 antibodies
WO2023011502A1 (zh) 含有抗il-4r抗体的稳定制剂
KR20230165828A (ko) 항-MUC16 x 항-CD3 이중특이적 항체를 함유하는 안정화된 제형
US20220031843A1 (en) Stabilized Formulations Containing Anti-CTLA-4 Antibodies
JP2023526359A (ja) アトピー性皮膚炎の処置のための抗il-36r抗体
TW202337497A (zh) 鼻內調配物及抗sars-cov-2棘蛋白抗體
WO2025226695A1 (en) Stable antibody formulation
US20250041411A1 (en) Stabilized Formulations Containing Anti-BCMA x Anti-CD3 Bispecific Antibodies
TW202541845A (zh) 穩定醫藥製劑
CN115957318A (zh) 一种双抗体组合物及其在制备治疗肝癌转移药物中的应用
CA3115708A1 (en) Formulations of anti-rsv antibodies and methods of use thereof
EA041921B1 (ru) Фармацевтическая композиция
HK1223835B (zh) 浓缩蛋白制剂及其用途